Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

SAN DIEGO, Sept. 12, 2024. Neurocrine Biosciences, Inc. today announced that its ERUDITE Phase 2 clinical study of investigational compound luvadaxistat (NBI-1065844) failed to meet its primary endpoint as a potential treatment to improve cognitive...

Articles similaires

Urinary Cadmium Levels Linked to Cognitive Impairment in Whites

drugs.com - 04/Sep 22:53

WEDNESDAY, Sept. 4, 2024 -- Among White, but not Black individuals, urinary cadmium (Cd) concentrations are associated with cognitive impairment,...

Greater Adherence to MIND Diet Linked to Reduced Cognitive Impairment

drugs.com - 22:25

WEDNESDAY, Sept. 18, 2024 -- Greater Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay (MIND) diet...

Aura Biosciences announces positive results from phase 2 end of study of bel─sar as a first─line treatment for early─stage choroidal melanoma

pharmabiz.com - 14/Sep 23:19

Aura Biosciences, Inc., a clinical─stage biotechnology company developing precision therapies for solid tumours designed to preserve organ function,...

In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin

drugs.com - 05/Sep 06:09

INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...

In a First-of-its-kind Fixed Dose Study, Once Weekly Insulin Efsitora Alfa Leads to A1C Reduction Similar to Daily Insulin

drugs.com - 05/Sep 06:09

INDIANAPOLIS, Sept. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-1 and QWINT-3...

Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria

drugs.com - 11/Sep 08:09

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3...

Dupixent Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria

drugs.com - 11/Sep 08:09

TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024. Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Dupixent (dupilumab) confirmatory Phase 3...

First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma

drugs.com - 09/Sep 20:09

HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

healthtechzone.com - 05/Sep 10:30

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

healthtechzone.com - 05/Sep 10:30

Les derniers communiqués

Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022

Rubriques :

Articles similaires

Les derniers communiqués